News headlines about Jazz Pharmaceuticals (NASDAQ:JAZZ) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.9816272884667 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Jazz Pharmaceuticals plc – (JAZZ) CEO Bruce C. Cozadd Sells 1,000 Shares (americanbankingnews.com)
- Jazz Pharmaceuticals (JAZZ) Shares Cross Above 200 DMA – Nasdaq – Nasdaq (nasdaq.com)
- Jazz Pharmaceuticals plc – (JAZZ) SVP Sells $84,033.18 in Stock (americanbankingnews.com)
- Jazz Pharmaceuticals plc – (JAZZ) CFO Matthew P. Young Sells 1,152 Shares (americanbankingnews.com)
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) traded down $0.24 during trading on Wednesday, reaching $150.74. 343,565 shares of the company’s stock traded hands, compared to its average volume of 437,445. The company has a market cap of $9,209.72, a PE ratio of 18.96, a price-to-earnings-growth ratio of 0.81 and a beta of 0.97. Jazz Pharmaceuticals has a one year low of $128.58 and a one year high of $163.75. The company has a current ratio of 3.29, a quick ratio of 3.15 and a debt-to-equity ratio of 0.57.
JAZZ has been the topic of a number of analyst reports. B. Riley restated a “buy” rating and issued a $206.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Sunday, December 3rd. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. Bank of America raised their price objective on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, February 20th. Finally, Deutsche Bank set a $170.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $180.19.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $150.00, for a total value of $150,000.00. Following the sale, the chief executive officer now directly owns 294,542 shares in the company, valued at approximately $44,181,300. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $148.65, for a total transaction of $29,730.00. Following the completion of the sale, the executive vice president now owns 21,669 shares in the company, valued at $3,221,096.85. The disclosure for this sale can be found here. Insiders have sold a total of 11,858 shares of company stock worth $1,745,093 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/2018/03/14/jazz-pharmaceuticals-jazz-earns-daily-news-impact-score-of-0-16/1927336.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.